AUS
NZ
UK
CA
USA
IND
Highlights
- Mesoblast secures AUD$72.7 million from top shareholder.
- Funding will support marketing strategy for Ryoncil upon FDA approval.
- Shares rise over 3% following the announcement.
Mesoblast (ASX:MSB), a developer of innovative therapies for inflammatory conditions, has announced a significant funding deal with its largest shareholder, Gregory George. This agreement involves the issuance of AUD$72.7 million in convertible notes, aimed at bolstering the company's marketing strategy for its lead cellular drug candidate, Ryoncil. This drug is designed for treating children suffering from steroid-refractory acute graft versus host disease, a serious complication that can arise after stem cell transplants.
The funding will be made available in tranches of USD$10 million, with the conversion price set at AUD$1.32 per share. This price reflects a 25% premium compared to the average weighted share price over the past five days. Following the announcement, Mesoblast's shares experienced a notable increase, trading up more than 3% as investors reacted positively to the news.
Gregory George, a prominent US investor associated with G to the Fourth Investments, has played a crucial role in this funding arrangement. Dr. Silviu Itescu, CEO and founder of Mesoblast, expressed gratitude for Mr. George's continued support, highlighting its importance in ensuring the company remains well-capitalized for the upcoming commercial launch of Ryoncil. Dr. Itescu stated, “We appreciate the ongoing support from our major shareholder in ensuring that the company is well-capitalized for commercial product launch and can hit the ground running immediately following approval of RYONCIL by FDA.”
The company anticipates that the decision from the US Food and Drug Administration (FDA) regarding Ryoncil will be announced by early next year. With this funding in place, Mesoblast is poised to accelerate its efforts in marketing the product, positioning itself to make an immediate impact upon receiving FDA approval.
As of the latest trading session, Mesoblast shares were valued at approximately AUD$1.16. The strategic funding deal is expected to enhance the company's ability to navigate the competitive landscape of medical therapies for inflammatory conditions, ultimately benefiting patients in need of effective treatments.
